Conference Track

Head and Neck Cancer

Source: CCO Independent Conference Coverage of the 2007 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

No Correlation Between Survival and EGFR, VEGF, and p53 Overexpression in Head and Neck Squamous Cell Cancer
DCE-MRI May Predict Treatment Response in HNSCC Patients
Taxane-Containing Induction Chemotherapy With Radiotherapy and Concurrent Cisplatin Toxic but Feasible in Advanced-Stage HNSCC
Axitinib Active and Well Tolerated in Advanced Thyroid Cancer
Alternating Chemotherapy/Radiotherapy Does Not Improve Functional Larynx Preservation or Survival Rates for Patients With Resectable Hypopharynx or Larynx Cancer
Intratumoral EGFR Antisense DNA Active and Safe in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Cetuximab Combined With Induction Chemotherapy and Chemoradiation Produces Complete Pathological Responses in Patients With Operable Head and Neck Cancer
Improved Survival Following Chemoradiation for Patients With Head and Neck Squamous Cell Carcinoma Positive for Human Papillomavirus
Cetuximab Added to Platinum-Based Chemotherapy Significantly Prolongs Survival for Patients With Recurrent or Metastatic SCCHN
Motesanib Diphosphate Active and Tolerable in Patients With Progressive Differentiated Thyroid Cancer
Vandetanib Provides Clinical Benefit for Advanced Hereditary Medullary Thyroid Cancer
Sorafenib Active in Patients With Metastatic Thyroid Cancer
Chemotherapy Alone After Induction Maintains Function and Does Not Impact Survival in Patients With Laryngopharyngeal Cancer
Neoadjuvant Chemotherapy Prior to Chemoradiation Tolerable and May Improve Survival Over Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Cancer
Intensity-Modulated Radiotherapy Superior to Conventional Radiation Therapy in Improving Local Control and Preserving Salivary Function in Stage II Nasopharyngeal Cancer

Expert Analysis

Head and Neck Cancer

Faculty:
James A. Bonner, MD Marshall Posner, MD Everett Vokes, MD
Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the prognostic significance of epidermal growth factor receptor overexpression in the setting of head and neck cancer
Summarize the relevance of the human papillomavirus to head and neck cancer
Discuss the role of chemoradiotherapy in the treatment of patients with head and neck cancer
Discuss the use of monoclonal antibodies in the treatment of head and neck cancer

Topics covered include:

EGFR as a prognostic indicator in head and neck cancer
Magnetic resonance imaging as a prognostic technique
The relevance of human papillomavirus in head and neck cancer
Alternating, sequential, and combined chemoradiotherapy
Intensity-modulated radiotherapy in nasopharyngeal carcinoma
Chemotherapy following a complete response to induction therapy
Cetuximab treatment of advanced head and neck cancer
Anti-EGFR antisense therapy
Novel agents for thyroid cancer

CME CREDIT INFORMATION

Release Date: 08/09/07

Expiration Date: 08/08/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.